Cargando…

Plasma chromogranin A is a marker of death in elderly patients presenting with symptoms of heart failure

Cardiovascular risk assessment remains difficult in elderly patients. We examined whether chromogranin A (CgA) measurement in plasma may be valuable in assessing risk of death in elderly patients with symptoms of heart failure in a primary care setting. A total of 470 patients (mean age 73 years) we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goetze, Jens P, Hilsted, Linda M, Rehfeld, Jens F, Alehagen, Urban
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3959729/ https://www.ncbi.nlm.nih.gov/pubmed/24532383 http://dx.doi.org/10.1530/EC-14-0017

Ejemplares similares

Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors
por: Baekdal, Jonas, et al.
Publicado: (2020)

Prognostic impact of chromogranin A in patients with acute heart failure
por: Kim, Hong Nyun, et al.
Publicado: (2021)

Biochemistry of the Endocrine Heart
por: Goetze, Jens P., et al.
Publicado: (2022)

Low Efficacy of Chromogranin A Elimination by Therapeutic Plasma Exchange for Treatment of Chromogranin A Tubulopathy
por: Hakroush, Samy, et al.
Publicado: (2021)

Acute effects of N‐terminal progastrin fragments on gastric acid secretion in man
por: Goetze, Jens P., et al.
Publicado: (2017)

Chromogranin/secretogranin proteins in murine heart: myocardial production of chromogranin A fragment catestatin (Chga(364–384))
por: Biswas, Nilima, et al.
Publicado: (2010)

Chromogranin A expression in plasma of critically ill patients
por: Lavaux, T, et al.
Publicado: (2010)

Left ventricular hemodynamic forces as a marker of mechanical dyssynchrony in heart failure patients with left bundle branch block
por: Eriksson, Jonatan, et al.
Publicado: (2017)

Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma
por: Andersen, Ulrik Ø, et al.
Publicado: (2020)

Clinical Usefulness of Plasma Chromogranin A in Pancreatic Neuroendocrine Neoplasm
por: Paik, Woo Hyun, et al.
Publicado: (2013)

Chromogranin A plasma levels predict mortality in COVID-19
por: De Lorenzo, Rebecca, et al.
Publicado: (2022)

Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.
por: Baudin, E., et al.
Publicado: (1998)

Decreased plasma Chromogranin A361-372 (Catestatin) but not Chromogranin A17-38 (Vasostatin) in female dogs with bacterial uterine infection (pyometra)
por: Jitpean, Supranee, et al.
Publicado: (2015)

Plasma androgen receptor and serum chromogranin A in advanced prostate cancer
por: Conteduca, Vincenza, et al.
Publicado: (2018)

Chromogranin A Cell Density as a Diagnostic Marker for Lymphocytic Colitis
por: El-Salhy, Magdy, et al.
Publicado: (2012)

Genetic variance and plasma concentration of CD93 is associated with cardiovascular mortality: Results from a 6.7-year follow-up of a healthy community-living elderly population
por: Alehagen, Urban, et al.
Publicado: (2020)

Chromogranin A – unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls
por: Gut, Paweł, et al.
Publicado: (2016)

Chromogranin A as a valid marker in oncology: Clinical application or false hopes?
por: Gkolfinopoulos, Stavros, et al.
Publicado: (2017)

Hypovolemia and reduced hemoglobin mass in patients with heart failure and preserved ejection fraction
por: Montero, David, et al.
Publicado: (2019)

The chromogranin A-derived peptides catestatin and vasostatin in dogs with myxomatous mitral valve disease
por: Höglund, Katja, et al.
Publicado: (2020)

Prediction of sudden death in elderly patients with heart failure
por: Ayesta, Ana, et al.
Publicado: (2018)

Dietary Supplementation with Selenium and Coenzyme Q(10) Prevents Increase in Plasma D-Dimer While Lowering Cardiovascular Mortality in an Elderly Swedish Population
por: Alehagen, Urban, et al.
Publicado: (2021)

The Emerging Roles of Chromogranins and Derived Polypeptides in Atherosclerosis, Diabetes, and Coronary Heart Disease
por: Watanabe, Takuya
Publicado: (2021)

Body mass index in chronic heart failure: association with biomarkers of neurohormonal activation, inflammation and endothelial dysfunction
por: Christensen, Heidi M, et al.
Publicado: (2013)

Chromogranin A: An Endocrine Factor of Pregnancy
por: Bralewska, Michalina, et al.
Publicado: (2023)

Mode of death in elderly and super‐elderly patients with acute heart failure: Insights from Japanese heart failure registry
por: Takabayashi, Kensuke, et al.
Publicado: (2021)

Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors
por: Hijioka, Masayuki, et al.
Publicado: (2014)

Chromogranin A as a Marker for Diagnosis, Treatment, and Survival in Patients With Gastroenteropancreatic Neuroendocrine Neoplasm
por: Wang, Yu-hong, et al.
Publicado: (2014)

The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors
por: Kim, Moonjin, et al.
Publicado: (2016)

Associations between chronic work stress and plasma chromogranin A/catestatin among healthy workers
por: Liu, Xin, et al.
Publicado: (2022)

Circulating Chromogranin A as A Marker for Monitoring Clinical Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors
por: Tian, Tiantian, et al.
Publicado: (2016)

The surging role of Chromogranin A in cardiovascular homeostasis
por: Tota, Bruno, et al.
Publicado: (2014)

Chromogranin A in the Laboratory Diagnosis of Pheochromocytoma and Paraganglioma
por: Bílek, Radovan, et al.
Publicado: (2019)

Chromogranin A regulates neuroblastoma proliferation and phenotype
por: Zhang, Dongyun, et al.
Publicado: (2019)

The mechanisms of chromogranin B-regulated Cl(−) homeostasis
por: Jiang, Qiu-Xing, et al.
Publicado: (2022)

Supplementation with Selenium and Coenzyme Q10 Reduces Cardiovascular Mortality in Elderly with Low Selenium Status. A Secondary Analysis of a Randomised Clinical Trial
por: Alehagen, Urban, et al.
Publicado: (2016)

Can BNP-guided therapy improve health-related quality of life, and do responders to BNP-guided heart failure treatment have improved health-related quality of life? Results from the UPSTEP study
por: Karlström, Patric, et al.
Publicado: (2016)

Chromogranin A as Serum Marker for Gastroenteropancreatic Neuroendocrine Tumors: A Single Center Experience and Literature Review
por: Nölting, Svenja, et al.
Publicado: (2012)

Prevalence of early stages of heart failure in an elderly risk population: the Copenhagen Heart Failure Risk Study
por: Gaborit, Freja Stoltze, et al.
Publicado: (2019)

PDGF-D gene polymorphism is associated with increased cardiovascular mortality in elderly men
por: Alehagen, Urban, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_smuq88uebpb2gegam619d61t9t